ALNY
NASDAQAlnylam Pharmaceuticals Inc.
News · 26 weeks72-70%
2025-10-262026-04-19
Mix4490d
- Insider23(52%)
- Other9(20%)
- SEC Filings7(16%)
- Earnings3(7%)
- Analyst2(5%)
Latest news
25 items- PRWhen Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in BiotechAUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, s
- PRAlnylam to Webcast Conference Call Discussing First Quarter 2026 Financial ResultsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via conference call on Thursday, April 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceut
- INSIDERSEC Form 4 filed by Mclaughlin Melissa4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mclaughlin Melissa3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SECSEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.DEFA14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- SECSEC Form DEF 14A filed by Alnylam Pharmaceuticals Inc.DEF 14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- PRNew Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger – − Findings Reinforce Consistent Benefits of Vutrisiran Across ATTR-CM Disease Spectrum, Including Patients with Most Advanced Disease and Diastolic Dysfunction − − Real-World Data Demonstrate High Adherence and Persistence of Quarterly HCP-Administered Dosing with Vutrisiran – − Pooled Phase 2 Safety Data Reinforce Encouraging Safety Profile for Zilebesiran Across a Broad Population of Patients with Hypertension − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therap
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
- PRAlnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30 am ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with Viz.ai and the American Heart Association, Alnylam is advancing a comprehensive, system‑level approach to address persistent challenges of underdiagnosis and fragmented care
- ANALYSTAlnylam Pharma downgraded by Jefferies with a new price targetJefferies downgraded Alnylam Pharma from Buy to Hold and set a new price target of $330.00
- PRAlnylam to Webcast TTR Investor WebinarAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company's website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam's progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company's flagship TTR franchise. The webinar will feature Alnylam's senior commercial and medical leaders, including: Tolg
- INSIDEREVP Chief R&D Garg Pushkal sold $1,524,796 worth of shares (4,713 units at $323.53), decreasing direct ownership by 20% to 18,693 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERChief Executive Officer Greenstreet Yvonne sold $947,581 worth of shares (2,933 units at $323.08), decreasing direct ownership by 3% to 95,695 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDEREVP, Chief Financial Officer Poulton Jeffrey V. sold $797,351 worth of shares (2,468 units at $323.08), decreasing direct ownership by 4% to 61,805 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDEREVP, Chief Commercial Officer Tanguler Tolga sold $745,984 worth of shares (2,309 units at $323.08), decreasing direct ownership by 6% to 34,297 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERCSO & EVP, Head of Research Fitzgerald Kevin Joseph sold $417,685 worth of shares (1,291 units at $323.54), decreasing direct ownership by 6% to 20,569 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- PRTenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease TherapeuticsAgreement Combines Tenaya's Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (NASDAQ:ALNY), the leading RNAi therape
- INSIDEREVP, Chief Financial Officer Poulton Jeffrey V. was granted 4,769 shares and sold $722,801 worth of shares (2,206 units at $327.65), increasing direct ownership by 4% to 64,273 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDEREVP Chief R&D Garg Pushkal was granted 4,769 shares and sold $1,130,131 worth of shares (3,492 units at $323.63), increasing direct ownership by 6% to 23,406 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERCSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 3,688 shares and sold $1,051,773 worth of shares (3,250 units at $323.62), increasing direct ownership by 2% to 21,860 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDEREVP, Chief Commercial Officer Tanguler Tolga was granted 4,769 shares and sold $523,584 worth of shares (1,598 units at $327.65), increasing direct ownership by 9% to 36,606 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDEREVP, CLO and Secretary Supran Bryan was granted 1,539 shares, increasing direct ownership by 12% to 14,565 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERChief Executive Officer Greenstreet Yvonne was granted 13,844 shares and sold $2,227,698 worth of shares (6,799 units at $327.65), increasing direct ownership by 8% to 98,628 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SECAlnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- SECSEC Form 144 filed by Alnylam Pharmaceuticals Inc.144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)